Daruka Mahadevan, MD, PhD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Daruka Mahadevan, MD, PhD
Daruka Mahadevan, MD, PhD, is a professor of medicine and chief of the Division of Hematology and Medical Oncology at The University of Texas Health Science Center at San Antonio. He is the director of the Institute of Drug Development and the associate director for clinical research at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. He also is an internationally recognized physician-scientist in hematology and medical oncology.
He received his Bachelor of Science degree in physiology and biochemistry from the University of Reading, England. He went on to the University of London to earn his doctorate in protein crystallography. He received his Bachelor of Medicine, and Bachelor of Surgery (MD equivalent) from King’s College Hospital Medical School at the University of London. He completed his residency in internal medicine at the University of Connecticut Health Center, and his hematology-oncology fellowship at the University of Arizona Health Sciences Center. Dr. Mahadevan is board-certified by the American Board of Internal Medicine and the American Board of Medical Oncology.
Mahadevan’s major area of interest is early-phase treatments for patients with pancreatic cancer, gastrointestinal stromal tumors, myelodysplastic syndromes and non-Hodgkin’s lymphoma, including chronic lymphocytic leukemia. He has led or co-led early-phase clinical trials investigating cancer agents first being tested in humans with funding from several National Institutes of Health grants and foundations supporting cancer research. In addition, he has successfully directed a drug discovery laboratory program based on his expertise in protein crystallography. This has led to his being awarded six U.S. patents for new drugs he developed that target novel driver oncogenes (new cancer mutations that initiate or continue cancer).
One of the new drugs he developed, amuvatinib, targeting c-Kit/c-Met/PDGFR/RAD51 has gone through Phase I and II clinical trials. As PI or co-PI on several National Institutes of Health (NIH) and foundation grants, he has established proof-of-concept and delivered on drug discovery - R01 (AKT PH domain inhibitors) and on drug development - NSF (Prostate cancer translational drug development), SPORE in Lymphoma (Aurora kinase inhibitor therapy for aggressive lymphomas) and SWOG Hope Foundation (targeted therapeutics for aggressive B- and T-cell non-Hodgkin Lymphomas).
Lastly, he has participated in monthly scientific leadership committee meetings at UACC, NCI external advisory board (EAB) meeting (Feb 2016, CCSG renewal) and yearly EAB meetings. In addition, he received an NCI P30 supplement (2017-2019) to study rare cancers by whole-exome sequencing of tumor vs. normal in collaboration with the UA Genomics Core. From 2016 to 2019, he was the Director of the Early Phase Therapeutics Program (‘Phase I Program’) and enrolled over 150 patients in novel first-in-human investigational agents in both solid and hematologic malignancies.
He continues to expand the bandwidth of the early-phase therapeutics portfolio and Investigator Initiated Studies.
Gender
- Male
Languages Spoken
- English
-
Credentials
Credentials
Positions
- Professor of Medicine, University of Texas Health Science Center San Antonio
- Chief, Division of Hematology-Medical Oncology, University of Texas Health Science Center San Antonio
- Director, Institute for Drug Development, UT Health San Antonio MD Anderson Cancer Center
- Associate Director, Clinical Research, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine, Medical Oncology
Education
Medical School: King's College Hospital Medical School, University of London, England, UK
Fellowship: Hematology/Oncology, University of Arizona College of Medicine, Tucson, AZ
Residency: Internal Medicine, University of Connecticut School of Medicine, Farmington, CT
Doctorate: Protein crystallography, Birkbeck College, University of London, England, UK
Fellowship: Research, National Institute of Health, Bethesda, MD - Locations & Contact
-
Research & Publications
Research & Publications
A comparative analysis of tumors and plasma circulating tumor DNA in 145 advanced cancer patients annotated by 3 core cellular processes
Larson K, Kannaiyan R, Pandey R, Chen Y, Babiker HM, Mahadevan D.
Cancers (Basel). 2020 Mar 16;12(3):701. doi: 10.3390/cancers12030701. PMID: 32188081; PMCID: PMC7140098.
View All Research & Publications
-
Clinical Trials
Clinical Trials
Type of Cancer
Solid Tumor
ClinicalTrials.gov Identifier
NCT03860272
Principal Investigator
Daruka Mahadevan, MD, PhD
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti CTLA-4 Monoclonal Antibody in Patients with Advanced Cancer and Select Tumor Types (CTMS# 19-0008)
This study is an open-label, Phase 1/2, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181) monotherapy and in combination with a human monoclonal IgG4 antibody (AGEN2034), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors. This study will also determine the…
ClinicalTrials.gov Identifier
NCT04164082
Principal Investigator
Daruka Mahadevan, MD, PhD
A031803, Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer CTMS#: 20-0004
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from…
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Daruka Mahadevan, MD, PhD
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB--A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors (CTMS# 21-0064)
Type of Cancer
Metastases
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Daruka Mahadevan, MD, PhD
A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with advanced unresectable and/or metastatic immune checkpoint inhibitor (ICI) refractory solid tumors or ICI naive MSS/MSI-low solid tumors (CT
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of Pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors